Key FDA Changes MedTech Manufacturers Need to Know 

The FDA has issued an update for MedTech Manufacturers to its List of FDA-Recognized Consensus Standards, published as Recognition List Number: 065 in the Federal Register, which modifies the standards used to support premarket review of medical devices. The updated standards became effective February 19, 2026. This notice marks a significant, ongoing update to the standards the agency recognizes for use in premarket submissions, including additions, withdrawals, and revisions.  

Purpose and Use 

• These changes help FDA MedTech manufacturers who choose to declare conformity to consensus standards when demonstrating compliance with regulatory requirements for medical devices. 

• These updated standards are intended to support more efficient regulatory review and enhance device safety and effectiveness by aligning with updated scientific and technical benchmarks. 

Key Updates for FDA MedTech Manufacturers

• MedTech Cybersecurity Addition: A major addition is the inclusion of a Consensus Report (CR) on medical technology cybersecurity:  AAMI CR515:2025, “Cybersecurity Consideration Unique to Machine-Learning Enabled Medical Devices“. This document addresses unique threats arising during data collection, product design, and maintenance of AI/ML-enabled devices. 

• Withdrawal and Replacement of Older Standards: The update continues the trend of withdrawing older standards and replacing them with newer versions to reflect technological advancements. 

• Scope of Changes: The modifications cover a wide array of fields, including anesthesiology devices, device biocompatibility, and materials. 

• Applicability: These modifications became applicable on February 19, 2026, and are incorporated into the FDA’s searchable database.  

Operational Impacts for Manufacturers and Developers 

Required Updates to Internal Documentation: Quality, Regulatory, and R&D teams will need to review updated standards in Recognition List No. 065 to determine: 

1. Whether current testing protocols remain aligned; 

2. Whether new or revised standards require changes to device design verification/validation; and 

3. Whether retired standards necessitate alternative approaches. 

These updates directly affect submission strategies for 510(k), De Novo, or PMA pathways:  

• Implications for Ongoing and Upcoming Submissions: Any submissions under development should be checked to confirm they use the latest FDA recognized standards. Using superseded standards can trigger FDA requests for supplemental information, which may extend review timelines. 

• Impact on Global Harmonization: Because many FDA-recognized standards mirror international consensus standards (e.g., ISO, IEC), the modifications may improve alignment with global markets, reducing redundant testing for companies operating internationally.  

Anticipated Benefits to Industry 

• Reduced Time-to-Market: Using updated recognized standards may reduce the need for additional justification and supplemental testing, leading to faster FDA clearance/review timelines for MedTech Manufactures.

• Improved Quality and Safety: Updated standards incorporate the latest scientific and engineering advances, enhancing device reliability and safety while reducing post-market risks.  

• Strengthened Regulatory Alignment: Regular updates ensure consistency with the FDA Modernization Act’s objective of enhancing regulatory efficiency and responsiveness to technological advancements. 

Compliance and Commenting Process 

Stakeholders may submit comments at any time regarding the recognized standards list. The FDA accepts: 

• Electronic submissions through Regulations.gov, which are posted publicly without redaction 

• Written submissions for comments containing confidential information 

FDA MedTech manufacturers should consider submitting feedback when emerging technologies or evolving scientific evidence warrants standard updates. 

Key Takeaways for Stakeholders 

• The new Recognition List Number: 065 updates the standards used in device premarket submissions. 

• The updates are effective immediately as of February 19, 2026.  

• Manufacturers should promptly review the updated standards and adjust their regulatory and testing strategies. 

• The revisions support efficient, science based regulatory oversight consistent with FDA modernization goals.  

• Stakeholders may provide comments at any time through FDA’s established channels.  

How MedEnvoy Can Support  

MedEnvoy supports FDA MedTech medical device manufacturers in navigating evolving guidance and standards by translating regulatory expectations into clear, actionable strategies. Our team provides end-to-end support across regulatory planning, FDA engagement, and clinical evidence development to help reduce uncertainty and avoid downstream delays. We assist with early FDA interactions, including premarket strategy and submission preparation. To learn more about our FDA Agent services, click here. If you have any questions regarding this summary or the accompanying guidance document, we encourage you to reach out to our regulatory experts, here.